WO1995018609A1 - Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof - Google Patents

Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof Download PDF

Info

Publication number
WO1995018609A1
WO1995018609A1 PCT/US1994/000089 US9400089W WO9518609A1 WO 1995018609 A1 WO1995018609 A1 WO 1995018609A1 US 9400089 W US9400089 W US 9400089W WO 9518609 A1 WO9518609 A1 WO 9518609A1
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
aii
mediation
lipoxygenase
consequences
Prior art date
Application number
PCT/US1994/000089
Other languages
French (fr)
Inventor
Jerry L. Nadler
Rama Devi Natarajan
Original Assignee
City Of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City Of Hope filed Critical City Of Hope
Priority to AU70906/94A priority Critical patent/AU7090694A/en
Priority to EP94919966A priority patent/EP0696193A4/en
Publication of WO1995018609A1 publication Critical patent/WO1995018609A1/en
Priority to US08/945,744 priority patent/US6191169B1/en
Priority to US09/691,845 priority patent/US6486181B1/en
Priority to US09/739,843 priority patent/US6893829B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11012—Linoleate 13S-lipoxygenase (1.13.11.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11031—Arachidonate 12-lipoxygenase (1.13.11.31), i.e. lipoxygenase-type-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Abstract

The discovery and regulation of a 12-LO isoform (hl 12-LO) expressed in human tissues and of a similar isoform in PVSMCs is described. Various ribozyme and chemical inhibitors of the hl 12-LO pathway are described. The involvement of this 12-LO pathway in AII induced hypertrophy is demonstrated. It is shown that HG culture potentiates the stimulatory effects of AII and HETE in vascular smooth muscles. A specific aspect of the invention is the discovery that activation of a 12-LO pathway in vascular smooth muscle accentuates AII induced vascular hypertrophic response in diabetes mellitus. Human therapy involving mediation of the hl 12-LO pathway is described.
PCT/US1994/000089 1992-08-28 1994-01-04 Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof WO1995018609A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU70906/94A AU7090694A (en) 1992-08-28 1994-01-04 Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof
EP94919966A EP0696193A4 (en) 1992-08-28 1994-01-04 Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof
US08/945,744 US6191169B1 (en) 1992-08-28 1996-05-03 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US09/691,845 US6486181B1 (en) 1992-08-28 2000-10-18 Human leukocutye 12-lipoxygenase and its role in the pathogenesis of disease states
US09/739,843 US6893829B2 (en) 1992-08-28 2000-12-20 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93666092A 1992-08-28 1992-08-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US93666092A Continuation-In-Part 1992-08-28 1992-08-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US43468195A Continuation-In-Part 1992-08-28 1995-05-04
US09/739,843 Continuation-In-Part US6893829B2 (en) 1992-08-28 2000-12-20 Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states

Publications (1)

Publication Number Publication Date
WO1995018609A1 true WO1995018609A1 (en) 1995-07-13

Family

ID=25468927

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1993/008106 WO1994005777A1 (en) 1992-08-28 1993-08-26 Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway
PCT/US1994/000089 WO1995018609A1 (en) 1992-08-28 1994-01-04 Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008106 WO1994005777A1 (en) 1992-08-28 1993-08-26 Inhibition of the formation or activity of human leukocyte 12-lipoxygenase pathway

Country Status (5)

Country Link
EP (2) EP0621895A4 (en)
JP (1) JPH07500254A (en)
AU (2) AU674339B2 (en)
CA (1) CA2077461C (en)
WO (2) WO1994005777A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034943A1 (en) * 1995-05-04 1996-11-07 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO1999058979A1 (en) * 1998-05-13 1999-11-18 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
US6103496A (en) * 1998-05-29 2000-08-15 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
US6893829B2 (en) 1992-08-28 2005-05-17 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171609B1 (en) 1999-04-12 2008-06-25 Lexicon Pharmaceuticals, Inc. Lipoxygenase proteins and polynucleotides encoding the same
CN1301847A (en) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 New polypeptide-lipoxidase 10 and polynucleotide codign such polypeptide
CN1313389A (en) * 2000-03-15 2001-09-19 上海博德基因开发有限公司 Polypeptide-human lipoxidase 9 and polynucleotide for coding it

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849445A (en) * 1983-12-14 1989-07-18 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
JPH0815851B2 (en) * 1987-10-09 1996-02-21 日産自動車株式会社 Differential limiting device

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Endocrinology, Vol. 134, No. 1, issued January 1994, J. GU et al., "Evidence that a Leukocyte Type of 12-Lipoxygenase is Expressed and Regulated by Angiotensin II in human Adrenal Glumerulosa Cells", pages 70-77, see Abstract. *
FASEB Journal, Vol. 6, issued 1992, J. GU et al., "Evidence for Expression of a New Form of 12-Lipoxygenase (12-LO) in Human Cells", page A1564, Abstract No. 3638, see entire Abstract. *
Proceedings of the National Academy of Sciences, USA, Vol. 87, issued March 1990, T. YOSHIMOTO et al., "Cloning and Sequence Analysis of the cDNA for Arachdonate 12-Lipoxygenase of Porcine Leukocytes", pages 2142-2146, see Abstract. *
Proceedings of the National Academy of Sciences, Vol. 90, issued June 1993, R. NATARANJAN et al., "Elevated Glucose and Angiotensin II Increase 12-Lipoxygenase Activity and Expression in Porcine Aortic Smooth Muscle Cells", pages 4947-4951, see Abstract and page 4951, cols. 1-2. *
Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 45, issued 1992, P.P.H. LEE et al., "Regulation of Proliferation of Rat Mammary Tumor Cells by Inhibitors of Cyclooxygenase and Lipoxygenase", pages 21-31, see Abstract. *
See also references of EP0696193A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893829B2 (en) 1992-08-28 2005-05-17 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO1996034943A1 (en) * 1995-05-04 1996-11-07 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
WO1999058979A1 (en) * 1998-05-13 1999-11-18 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
US6103496A (en) * 1998-05-29 2000-08-15 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids
US6569644B2 (en) 1998-05-29 2003-05-27 Vanderbilt University Isolated and purified 12R-lipoxygenase protein and nucleic acids

Also Published As

Publication number Publication date
AU7090694A (en) 1995-08-01
CA2077461A1 (en) 1994-03-01
EP0696193A1 (en) 1996-02-14
WO1994005777A1 (en) 1994-03-17
EP0621895A1 (en) 1994-11-02
AU674339B2 (en) 1996-12-19
CA2077461C (en) 2000-02-15
EP0621895A4 (en) 1996-11-27
JPH07500254A (en) 1995-01-12
AU4840393A (en) 1994-03-29
EP0696193A4 (en) 1996-11-27

Similar Documents

Publication Publication Date Title
CA2109084A1 (en) Biofilm reduction method
EP1238667A3 (en) Use of benzothiophenes for treatment of hypercholesterolaemia
AU6613896A (en) Chemical compounds
AU8040391A (en) A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
CA2177868A1 (en) Process for making a training pant having a unitary waist elastic system
NO942813D0 (en) Spray peeled nabumeton
TR199800853T2 (en) The use of epinastine in the treatment of pain.
AU7128196A (en) Synergistically active herbicidal mixtures
ZA9510727B (en) 2-¬(Dihydro) pyrazol-3'-yloxymethylene¾ anilides their preparation and their use
PT907365E (en) NEW FORMULATION
AU697311B2 (en) Combined preparation for the therapy of immunological diseases
AU6801496A (en) Film for the treatment of soils by fumigation
EP0696193A1 (en) Human leukocyte 12-lipoxygenase, mediation of its pathway, and consequences thereof
MD990252A (en) Method of controlling the phytopathogenic diseases of grain crops and the fungicidal composition containing 4-phenoxychinoline
WO2001081332A3 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
AU3396893A (en) Pulsimeter capable of properly evaluating amount of exercise at arbitrary time
AU1139897A (en) Use of aqueous solutions or dispersions of copolymers of carboxyl-group-containing monomers, ethylenically unsaturated acetals, cetals or orthocarboxylic acid esters and optionally other copolymerisable monomers as leather tanning agents
TW360493B (en) Fungicidal mixtures and a method of controlling fungi using the same
AU1669092A (en) Use of torasemide for the treatment of cerebral oedema
WO1996021015A3 (en) Combination gene delivery vehicles
EP0958835A4 (en) Preventive/remedy for frequent urination and urinary incontinence
WO1997024138A3 (en) Medical use of proteases
AU4539396A (en) Fungicidal aza-heterocycloalkenes
AU6129096A (en) Use of pyrrolidine derivatives in the treatment of alcoholism

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2157017

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 507278

Country of ref document: US

Date of ref document: 19950830

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1994919966

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1994919966

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994919966

Country of ref document: EP